Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235196 | 0.84 | NPSR1 (0.56) | NPSR1P2RX3MAPTADORA3ALDH1A1 | |
| SCHEMBL8873522 | 0.83 | ALDH1A1 (0.49) | ADORA3ALDH1A1LMNACYP3A4KMT2A | |
| SCHEMBL7356240 | 0.82 | ALDH1A1 (0.47) | NPSR1ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL3978746 | 0.81 | SMN1; SMN2 (0.44) | MAPTADORA3ALDH1A1LMNACYP3A4 | |
| SCHEMBL4181999 | 0.81 | SMN1; SMN2 (0.40) | P2RX3MAPTADORA3ALDH1A1CYP1A2 | |
| SCHEMBL242052 | 0.76 | ALDH1A1 (0.41) | NPSR1ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL3624794 | 0.76 | ALDH1A1 (0.39) | NPSR1ALDH1A1LMNAADORA2AADORA2B | |
| SCHEMBL13746372 | 0.75 | PDE4A (0.43) | NPSR1ALDH1A1LMNAADORA2AADORA2B | |
| SCHEMBL7321137 | 0.74 | CASP6 (0.50) | NPSR1MAPTALDH1A1LMNACYP1A2 | |
| SCHEMBL1332558 | 0.74 | ADORA2B (0.43) | ALDH1A1LMNAKMT2AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | GABRB1, GRPR, GIPR | NPSR1 48/4885P2RX3 156/4885MAPT 3675/4885 |
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | NPSR1 47/4885P2RX3 57/4885MAPT 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.